Results 141 to 150 of about 253,827 (253)

Effective Performance of the 2022 American College of Rheumatology/EULAR Classification Criteria for Antineutrophil Cytoplasmic Antibody–Associated Vasculitis in Pediatric Patients: An ARChiVe Study

Arthritis &Rheumatology, EarlyView.
Objective To assess the 2022 American College of Rheumatology (ACR)/EULAR classification criteria for antineutrophil cytoplasmic antibody–associated vasculitis (AAV) in children with chronic small‐to‐medium vessel vasculitis. Methods A cohort of 574 patients, identified by physician's diagnosis (MD‐diagnosis) in A Registry of Childhood Vasculitis, was ...
David A. Cabral, Else S. Bosman, Nick McPhate, Simranpreet K. Mann, Kirandeep K. Toor, Kimberly A. Morishita, Raashid Luqmani, Michael W. Beresford, James Bistolarides, Sarah Campillo, Sirirat Charuvanij, Kathryn Cook, Paul Dancey, Marietta de Guzman, Samundeeswari Deepak, Barbara Eberhard, Melissa Elder, Samuel Gagne, Katie Harrison, Adam Huber, Archana Khan, Susan Kim, Marisa S. Klein‐Gitelman, Tzielan C. Lee, Suzanne C. Li, Neil Martin, Flora McErlane, L. Nandini Moorthy, Alvaro H. Orjuela, Jonathan Park, Phil Riley, Alan M. Rosenberg, Susan Shenoi, Vidya Sivaraman, Sodality Sutnga, Tamara Tanner, Stacey E. Tarvin, Marinka Twilt, Linda Wagner‐Weiner, Rae S. M. Yeung, Kelly L. Brown, for the ARChiVe Investigators Network within the PedVas Initiative   +41 more
wiley   +1 more source

Integrated Clinical and Proteomic Profiling of CD19 Chimeric Antigen Receptor T Cell Therapy in Progressive Systemic Sclerosis

Arthritis &Rheumatology, EarlyView.
Objective To characterize the clinical, immunologic, and proteomic changes associated with CD19 chimeric antigen receptor T cell therapy in patients with progressive systemic sclerosis (SSc). Methods Patients with progressive SSc received CD19 chimeric antigen receptor (CAR)‐T cell therapy and were observed longitudinally for safety, clinical efficacy,
Chenhan Jia, Wanyi Lin, Zhangyi Zhao, Fenglin Wu, Chaoyu Gu, Yuankai Sun, Zhe Ding, Chang Wei, Xinyu Li, Cuiwei Xie, Peng Xia, Zhen Xia, Xuesong Liu, Shaoying Yang, Chunyan Zhang, Hanlin Yin, Liangjing Lu   +16 more
wiley   +1 more source

Efficacy and Safety of Nanoencapsulated Sirolimus Plus Pegadricase: Results From the Randomized, Placebo‐Controlled Phase 3 Trials

Arthritis &Rheumatology, EarlyView.
Objective DISSOLVE I and II examined the efficacy and safety of nanoencapsulated sirolimus (NAS) plus pegadricase (NASP) in patients with uncontrolled gout (UG). Methods In these double‐blind, placebo‐controlled Phase 3 trials of NASP, patients were randomized 1:1:1 to infusions of high‐dose (HD) or low‐dose (LD) NAS plus pegadricase (HD NASP, LD NASP,
Herbert S. B. Baraf, Puja P. Khanna, Milan Petronijevic, Mamuka Lortkipanidze, Anand Patel, Kwabena Ayesu, Michael H. Pillinger, Atul Singhal, Joanna Sobierska, Jacquie Christie, Peter Traber, Rehan Azeem, Wesley DeHaan, Hugues Santin‐Janin, Bhavisha Desai, Alan Kivitz   +15 more
wiley   +1 more source

Kinetic characteristics of purified H+,K+-ATPase from parietal cells plasma membrane under stress-induced stomach ulcer

Current Issues in Pharmacy and Medical Sciences
In the present study of kinetic parameters of purified H+,K+-ATPase of rats plasma membrane under stress-induced stomach ulcer were investigated. It was established that elution profile of the protein had one peak under control conditions and two peaks –
Eugenia Strotska, Yana Raetska, Sergey Mandryk, Lyudmila Ostapchenko   +3 more
doaj  

Role of Helicobacter Pylori in the Development of Gastric Ulcer [PDF]

To investigate on the role of H.Pylori in the development of gastric ulcer. It is a bacteria that can cause infection in the stomach or duodenum.
Shreemathy, K. (Kumar), Aidana, K. K. (Kanatbek)   +1 more
core  

Deucravacitinib in Active Psoriatic Arthritis: Efficacy and Safety Up to 52 Weeks From the Randomized, Double‐Blind, Phase 3 POETYK PsA‐2 Trial

Arthritis &Rheumatology, EarlyView.
Objective To assess the efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with psoriatic arthritis (PsA) who were naive to biologic disease‐modifying antirheumatic drugs or received tumor necrosis factor inhibitors. Methods In the 52‐week, double‐blind, placebo‐controlled, phase 3 Program for Evaluation
Philip J. Mease, Vinod Chandran, April W. Armstrong, Ricardo Blanco, Alexis Ogdie, Evan L. Siegel, Alice B. Gottlieb, Xiaofeng Zeng, Diamant Thaçi, Mitsumasa Kishimoto, Hendrik Schulze‐Koops, Alan Kivitz, Eva Dokoupilová, Akimichi Morita, Eric M. Ruderman, Michael Plewinski, Kejia Wang, Caroline Sardinas, Eleni Vritzali, John Vaile, Atul Deodhar   +20 more
wiley   +1 more source

Plasma Proteome Reflects Tissue Damage and Clinical Manifestations in Patients With Inflammatory Myopathies

Arthritis &Rheumatology, EarlyView.
Objective Tissue‐specific biomarkers that are reliable and associated with clinical manifestations of idiopathic inflammatory myopathy (IIM) are lacking. The blood circulation in individuals serves as a central conduit, allowing communication between tissues and facilitating clearance and recycling of tissue‐derived proteins.
Yue‐Bei Luo, Josefin Kenrick, Angeles S. Galindo‐Feria, Antonella Notarnicola, Ana Daniela Ulloa Navas, Irene Peralta‐Garcia, Orane Demuynck, Andrea Kemp, Valérie Leclair, Karin Lodin, Eveline Van Gompel, Lara Dani, Fabricio Espinosa‐Ortega, Maryam Dastmalchi, Leonid Padyukov, Charlotta Preger, María Bueno Álvez, Mathias Uhlén, Peter Nilsson, Fredrik Edfors, Lina‐Marcela Diaz‐Gallo, Elisa Pin, Ingrid E. Lundberg, Begum Horuluoglu   +23 more
wiley   +1 more source

Higher risk of Long COVID among patients with autoimmune rheumatic diseases and immunomodulatory therapy: a retrospective cohort analysis of national US data.

Arthritis &Rheumatology, Accepted Article.
Background Little is known about the prevalence of and factors associated with Long COVID in patients with autoimmune rheumatic diseases (AIRDs). Methods We conducted a retrospective cohort study using data from the National Clinical Cohort Collaborative (N3C).
Namrata Singh, A. Jerrod Anzalone, Holland Stevenson, Londyn Robinson, Lesley E. Jackson, Sandra E. Safo, Zachary Butzin‐Dozier, Kaleb Michaud, Maria I. Danila, Jasvinder A. Singh, Rena C. Patel, on behalf of the National Clinical Cohort Collaborative (N3C) Consortium   +11 more
wiley   +1 more source

Efficacy and safety of empagliflozin for treating neutropenia and neutrophil dysfunction in paediatric patients with glycogen storage disease type Ib: A systematic review and meta‐analysis

British Journal of Clinical Pharmacology, EarlyView.
Aims Glycogen storage disease type Ib (GSD‐Ib) is a rare genetic disorder causing neutropenia and neutrophil dysfunction in children. G‐CSF has been the primary treatment, but emerging data support the potential of empagliflozin, an SGLT2 inhibitor, as a promising investigational option.
Elizabeth Iwasyk, Ryan Jin, Fabio Tuzzolino, Giusy Ranucci, Donatella Madonia, Alessio Provenzani   +5 more
wiley   +1 more source

Tragopogon coelesyriacus Boiss. attenuates ethanol-induced gastric ulcer in vivo: modulation of oxidative stress, inflammation, and apoptosis. [PDF]

PLoS One
Ibrahim Alsharif H, Khaled Abu-Sini M, Ismael A, Farhad Abdulqadir N, S El-Sayyad G, Jabbar AAJ, Basil Abu Jalboush S, Fahad Mosallam Almehmadi R, Salem Al-Qaisi T, Alqaisi KM.   +9 more
europepmc   +1 more source